Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

The end of the road for prostate specific antigen testing?

Nna E.

Niger J Clin Pract. 2013 Oct-Dec;16(4):407-17. doi: 10.4103/1119-3077.116871. Review.

2.

Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers.

Chan SW, Nguyen PN, Violette P, Brimo F, Taguchi Y, Aprikian A, Chen JZ.

Cancer Med. 2013 Feb;2(1):63-75. doi: 10.1002/cam4.49. Epub 2013 Feb 3.

3.

Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.

Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG.

Urol Oncol. 2013 Jul;31(5):566-71. doi: 10.1016/j.urolonc.2011.04.001. Epub 2011 May 19.

4.

Current biomarkers for diagnosing of prostate cancer.

Stephan C, Jung K, Ralla B.

Future Oncol. 2015;11(20):2743-55. doi: 10.2217/fon.15.203. Epub 2015 Sep 11. Review.

PMID:
26358139
5.

Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.

Dimitriadis E, Kalogeropoulos T, Velaeti S, Sotiriou S, Vassiliou E, Fasoulis L, Klapsas V, Synesiou M, Apostolaki A, Trangas T, Pandis N.

Anticancer Res. 2013 Jan;33(1):191-7.

PMID:
23267145
6.

Urinary biomarkers in prostate cancer detection and monitoring progression.

Wu D, Ni J, Beretov J, Cozzi P, Willcox M, Wasinger V, Walsh B, Graham P, Li Y.

Crit Rev Oncol Hematol. 2017 Oct;118:15-26. doi: 10.1016/j.critrevonc.2017.08.002. Epub 2017 Aug 19. Review.

PMID:
28917266
7.

Molecular prostate cancer pathology: current issues and achievements.

Schalken JA, Bergh A, Bono A, Foster C, Gospadarowicz M, Isaacs WB, Rubin M, Schröder F, Tribukait B, Tsukamotot T, Wiklund P.

Scand J Urol Nephrol Suppl. 2005 May;(216):82-93. Review.

PMID:
16019760
8.

Biomarkers in localized prostate cancer.

Ferro M, Buonerba C, Terracciano D, Lucarelli G, Cosimato V, Bottero D, Deliu VM, Ditonno P, Perdonà S, Autorino R, Coman I, De Placido S, Di Lorenzo G, De Cobelli O.

Future Oncol. 2016 Feb;12(3):399-411. doi: 10.2217/fon.15.318. Epub 2016 Jan 15. Review.

9.

Advances in biomarkers for the early diagnosis of prostate cancer.

Cao DL, Yao XD.

Chin J Cancer. 2010 Feb;29(2):229-33. Review.

10.

Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM.

Sci Transl Med. 2011 Aug 3;3(94):94ra72. doi: 10.1126/scitranslmed.3001970.

11.

Comprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: focusing on Asians and Asian countries.

Okihara K, Ochiai A, Kamoi K, Fujizuka Y, Miki T, Ito K.

Int J Urol. 2015 Apr;22(4):334-41. doi: 10.1111/iju.12701. Review.

12.

Prostate-specific antigen screening: pro.

Loeb S, Catalona WJ.

Curr Opin Urol. 2010 May;20(3):185-8. doi: 10.1097/MOU.0b013e3283384047. Review.

13.

Influence of Long-Distance Bicycle Riding on Serum/Urinary Biomarkers of Prostate Cancer.

Heger Z, Gumulec J, Ondrak A, Skoda J, Zitka Z, Cernei N, Masarik M, Zitka O, Adam V.

Int J Mol Sci. 2016 Mar 17;17(3):377. doi: 10.3390/ijms17030377.

14.

DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy.

Jacobs C, Tumati V, Kapur P, Yan J, Hong D, Bhuiyan M, Xie XJ, Pistenmaa D, Yu L, Hsieh JT, Saha D, Kim DW.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):729-35. doi: 10.1016/j.ijrobp.2014.03.035. Epub 2014 May 24.

15.

Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, Meyer HA, Bögemann M, Miller K, Friedersdorff F.

Clin Chem. 2013 Jan;59(1):280-8. doi: 10.1373/clinchem.2012.195560. Epub 2012 Dec 4.

16.

Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine.

Cao DL, Ye DW, Zhu Y, Zhang HL, Wang YX, Yao XD.

Prostate Cancer Prostatic Dis. 2011 Jun;14(2):166-72. doi: 10.1038/pcan.2011.2. Epub 2011 Feb 15.

PMID:
21321584
17.

Urine biomarkers in prostate cancer.

Ploussard G, de la Taille A.

Nat Rev Urol. 2010 Feb;7(2):101-9. doi: 10.1038/nrurol.2009.261. Epub 2010 Jan 12. Review.

PMID:
20065953
18.

Urine markers in monitoring for prostate cancer.

Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J.

Prostate Cancer Prostatic Dis. 2010 Mar;13(1):12-9. doi: 10.1038/pcan.2009.31. Epub 2009 Aug 4. Review.

PMID:
19652665
19.

[Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer].

Mazzola CR, Ghoneim T, Shariat SF.

Prog Urol. 2011 Jan;21(1):1-10. doi: 10.1016/j.purol.2010.07.004. Epub 2010 Aug 14. Review. French.

PMID:
21193139
20.

Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?

Duffy MJ.

Ann Clin Biochem. 2011 Jul;48(Pt 4):310-6. doi: 10.1258/acb.2011.010273. Epub 2011 Apr 27. Review.

PMID:
21525152

Supplemental Content

Support Center